About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Not Yet RecruitingPhase 1NCT07067099

Neutralizing Interferon Type 1 in Hidradenitis Suppurativa

The purpose of the study is to evaluate the safety and type 1 Interferon (IFN) neutralization in patients with refractory severe Hidradenitis Suppurativa (Hurley stage III) after transfusion of plasma...

Lead sponsor: Centre Hospitalier Universitaire de Besancon•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Charline Vauchy, PhD.

CONTACT

+33381218875 cvauchy@chu-besancon.fr

Sponsors

Lead Sponsor

Centre Hospitalier Universitaire de Besancon

Collaborators

Etablissement Français du Sang

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Men and women aged over 18
•Patients with Hidradenitis suppurativa (Hurley stages II-III)
•Disease affecting at least two distinct anatomical areas,
•Total count of abscesses (A) and inflammatory nodules (N) ≥ 3
•IHS4 score ≥ 11
•Treatment of pain with opioids (≥ 20 mg/day)
•Resistance to previous use (for at least 3 months) of systemic antibiotics and TNF inhibitors (infliximab or adalimumab) or anti-IL17 (secukinumab).
•Vaccinations against SARS-CoV-2 and influenza up to date (or able to be carried out prior to the study procedure)
•Women using an effective method of contraception
•Signed informed consent

Exclusion Criteria

•Active viral infection: herpes, VZV, HIV, HBV, HCV
•Active bacterial infection requiring systemic antibiotics
•Known allergy to blood components/plasma proteins
•Poor myocardial function (increased risk of for transfusion-associated circulatory overload) (symptomatic left ventricular failure and ejection fraction \< 40%)
•Pregnant women
•Subjects with no social security coverage

Related studies

RECRUITINGPhase 2

A Study With CIT-013 in HS Patients

NCT06993233 · Hidradenitis Suppurativa (HS)

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

NCT07316192 · Hidradenitis Suppurativa (HS)

RECRUITINGPhase 1

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

NCT07155239 · Hidradenitis Suppurativa (HS)

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

NCT07021495 · Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), and more

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT07123038 · Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 16, 2025Terms

Trial snapshot

StatusNOT_YET_RECRUITING

PhasePHASE1

Enrollment6

Start dateSep 2025

Last updatedJul 16, 2025

Condition

Hidradenitis Suppurativa (HS)

Locations shown

CHU Besançon

Besançon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 16, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions